A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)
10.3802/jgo.2021.32.e31
Saved in:
Main Authors: | Lee, Yong Jae, Lim, Myong Cheol, Kim, Byoung-Gie, Ngoi, Natalie YL, Choi, Chel Hun, Park, Sang-Yoon, Tan, David SP, Go, Yunjung, Lee, Jung-Yun |
---|---|
Other Authors: | DEPT OF MEDICINE |
Format: | Article |
Published: |
Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy
2021
|
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/186260 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
by: Kim, YN, et al.
Published: (2023) -
Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
by: Tan, DS, et al.
Published: (2021) -
Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
by: Tan, David SP, et al.
Published: (2021) -
Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant
by: Soon, Jonathan Jian Hao, et al.
Published: (2023) -
Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial
by: Wysham, Weiya Z, et al.
Published: (2023)